Led by Senior Editor in Chief Sundar Jagannath, Clinical Lymphoma, Myeloma and Leukemia is one of the latest additions to the ESMO family of journals.
Clinical Lymphoma, Myeloma and Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia.
What type of papers does Clinical Lymphoma Myeloma and Leukemia publish?
The Editors welcome the submission of articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
Why publish with Clinical Lymphoma Myeloma and Leukemia?
- Journal’s Impact Factor 2.822 (2021) and CiteScore 3.3 (2021)
- Rigorous peer review by noted experts in the field
ESMO members are entitled to receive a 20% discount on the journal's article publication charge for all papers submitted after January 1st 2023. Find out more about joining ESMO